Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.68 |
| ▸ | DHODH | Q02127 | 2/20 | 0.68 |
| ▸ | RXRA | P19793 | 2/20 | 0.59 |
| ▸ | RXRB | P28702 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 2/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.54 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.54 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.54 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid SCHEMBL28361078 | 0.90 | KMO (0.66) | KMODHODHRXRARXRBCNR2 | |
| SCHEMBL8444347 | 0.90 | KMO (0.66) | KMODHODHRXRARXRBLMNA | |
| SCHEMBL29382709 | 0.87 | PARP1 (0.65) | KMOGAAPARP1 | |
| SCHEMBL142937 | 0.87 | PARP1 (0.65) | KMOGAAPARP1 | |
| SCHEMBL14406 | 0.87 | PARP1 (0.65) | KMOGAAPARP1 | |
| SCHEMBL29904709 | 0.87 | KMO (0.86) | KMORXRARXRBLMNAGAA | |
| SCHEMBL30725957 | 0.87 | KMO (0.86) | KMORXRARXRBLMNAGAA | |
| SCHEMBL71238 | 0.87 | KMO (0.86) | KMORXRARXRBLMNAGAA | |
| SCHEMBL31331712 | 0.86 | RXRA (0.69) | KMODHODHRXRARXRB | |
| SCHEMBL2610268 | 0.86 | RXRA (0.69) | KMODHODHRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910316-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | claimed |
| EP-1910316-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | claimed |
| US-7268154-B2 | Substituted triazole compounds | HOFFMAN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | claimed |
| JP-2007519744-A | — | — | 2007-07-19 | — | — | JP | claimed |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | claimed |
| WO-2007012579-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | WO | claimed |
| US-20070021475-A1 | Substituted triazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | claimed |
| EP-1716158-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2006-11-02 | — | — | EP | claimed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | claimed |
| US-20230195003-A1 | ELECTROPHOTOGRAPHIC PHOTORECEPTOR, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJIFILM BUSINESS INNOVATION CORP. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | Technische Universität Dresden (DE) | 2022-01-04 | — | — | US | disclosed |
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | Technische Universität Dresden (DE) | 2022-01-04 | — | — | US | disclosed |
| US-20210139521-A1 | DIARYL TREHALOSE COMPOUNDS AND USES THEREOF | THE UNIV OF MONTANA (US) | 2021-05-13 | — | — | US | disclosed |
| EP-3819006-A1 | COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-0794789-A4 | INHIBITORS OF PRENYL TRANSFERASES | UNIV PITTSBURGH (US) | 1999-05-26 | — | — | EP | disclosed |
| US-5824691-A | CARDIOVASCULAR, CEREBROVASCULAR, RENAL DISEASES; SHOCK, ARTERIOSCLEROSIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-20 | — | — | US | disclosed |
| EP-0794789-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1997-09-17 | — | — | EP | disclosed |
| WO-1996021456-A1 | INHIBITORS OF PRENYL TRANSFERASES | UNIVERSITY OF PITTSBURGH (US) | 1996-07-18 | — | — | WO | disclosed |
| EP-0699185-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+ /H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-03-06 | — | — | EP | disclosed |
| WO-1994026709-A1 | GUANIDINE DERIVATIVES AS INHIBITORS OF Na+/H+ EXCHANGE IN CELLS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021475-A1 | Substituted triazole derivatives | GPR3, GRIN3A, GRIK3 | KMO 202/4885DHODH 3301/4885RXRA 744/4885 |
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | TMSB10, TMSB4X, TBCA | KMO 4330/4885DHODH 1982/4885RXRA 2730/4885 |
| US-20210139521-A1 | DIARYL TREHALOSE COMPOUNDS AND USES THEREOF | TREH, STT3B, DDOST | KMO 4115/4885DHODH 662/4885RXRA 4655/4885 |
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | CTSV, CTSB, CTSS | KMO 1212/4885DHODH 3226/4885RXRA 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.